Programs in immuno-oncology - Autologous

CAR-T NKR-2 (THINK trial – NCT03018405 - Phase I / Ongoing study)
CAR-T NKR-2 (THINK trial – NCT03018405 - Phase I / Ongoing study)
CAR-T NKR-2 (THINK trial – NCT03018405 - Phase I / Ongoing study)
  • Discover
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3

THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers, including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). The trial will test three dose levels adjusted to body weight: up to 3x10(8), 1x10(9) and 3x10(9) CAR-T NKR-2 cells. At each dose, the patients will receive three successive administrations, two weeks apart, of CAR-T NKR-2 cells. The dose escalation part of the study will enroll up to 24 patients while the extension phase would enroll 86 additional patients. Related Partners in Belgium: Institut Bordet, Cliniques Universitaires Saint-Luc, UZGhent.

More information about CAR-T NKR-2 THINK trial protocol (NCT03018405)

CAR-T NKR-2 (CMCS1 trial - NCT02203825 - Phase Ia / study completed)
CAR-T NKR-2 (CMCS1 trial - NCT02203825 - Phase Ia / study completed)
CAR-T NKR-2 (CMCS1 trial - NCT02203825 - Phase Ia / study completed)
  • Discover
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3

Autologous CAR-T NKR-2 cell therapy has been evaluated clinically in cancer patients suffering from Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM), two blood related cancers, together constituing more than 50% of all blood cancers. This study (ClinicalTrials.govNCT02203825) was completed in September 2016 at Dana Farber Cancer Institute (Boston, MA – USA), with a successful safety follow-up for all dose level cohorts. There were no cases of cytokine release syndrome, cell-related neurotoxicity, auto-immunity, or CAR-T related death. Related Partners: Dartmouth College – Celdara Medical – Dana Farber Cancer Institute – Institut Curie.

More information about CAR-T NKR-2 trial protocol (NCT02203825)

CAR-T NKR-3
CAR-T NKR-3
CAR-T NKR-3
  • Discover
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3

NKR-3 is a CAR-T using NKp30, a NK receptor very similar to NKG2D, although using a different set of ligands (B7H6 being one of them). Autologous and allogeneic CAR-T NKR-3 are preclinically evaluated in mouse models.

CAR-T B7H6
CAR-T B7H6
CAR-T B7H6
  • Discover
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3

B7H6 is a more traditional antibody based CAR (using an antibody and not a receptor of NK cells), but it is the ligand of NkP30 and is also present on many different cancer cells. Autologous and allogeneic NkP30 and B7H6 are preclinically evaluated in mouse models.

Programs in immuno-oncology - Allogeneic

CAR-T NKR-2
CAR-T NKR-2
CAR-T NKR-2
  • Discover
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3

Want to see more

Not familiar with clinical trials?
Find all the answers on our clinical trials FAQ section.